MDM2 and lung cancer: In this study, we identified miR-1827 as a novel regulator for p53 by targeting MDM2. miR-1827 was recently reported to target L-MYC, and the nucleotide polymorphism for the miR-1827 binding site at the 3′-UTR of L-MYC is associated with increased risk for lung cancer, suggesting a potential role of miR-1827 in suppressing lung cancer [31].